The EEF2K Knockout Raji Polyclonal Cells (Homo sapiens) are a CRISPR/Cas9-mediated polyclonal knockout cell population generated from the Raji B lymphocyte line, with targeted disruption of the eukaryotic elongation factor 2 kinase (EEF2K) gene. This polyclonal pool lacks EEF2K protein expression, providing a genetically heterogeneous model that avoids clonal selection artifacts. The cells are supplied as a proliferating culture, ready for immediate use in functional studies of translation elongation control.
The Raji cell line is an EBV-positive B lymphocyte model established from a Burkitt’s lymphoma patient, extensively used to study humoral immunity and B cell lymphoma biology. Raji cells express key B cell markers, secrete immunoglobulins, and maintain robust mTOR and AMPK signaling pathways, making them an ideal host for investigating the regulatory networks that link nutrient sensing, stress responses, and protein synthesis in malignant and activated B cells.
EEF2K encodes a calcium/calmodulin-dependent kinase that selectively phosphorylates eukaryotic elongation factor 2 (EEF2) on Thr56, inhibiting its activity and slowing translational elongation. Activation of EEF2K is mediated by Ca2+/calmodulin, AMPK (PRKAA1/2), and PKA, while inhibition occurs through mTORC1 (MTOR/RPTOR) and insulin/IGF-1 signaling. In the Raji knockout background, disruption of EEF2K eliminates the phosphorylation of EEF2, leading to persistent elongation and altered ribosome dynamics. The pathway involves direct interactions with calmodulin, EEF2, and ribosomal subunits, and feeds into stress granule assembly and global protein homeostasis. Key pathway nodes affected include the ribosomal protein family (RPLs), PRKAA1, MTOR, and RPTOR.
In Raji B cells, EEF2K serves as a metabolic checkpoint that adjusts translation rates in response to oncogenic and immune signals. EBV-driven growth and high secretory demands place a premium on protein synthesis control, and disruption of EEF2K can reveal vulnerabilities in lymphoma cell survival. This knockout model allows precise dissection of how loss of elongation regulation impacts proliferation, antibody output, and sensitivity to metabolic or chemotherapeutic stress, positioning EEF2K as a candidate target in B cell malignancies and antibody-mediated disorders.
The EEF2K knockout Raji polyclonal cells are amenable to a range of biochemical and functional assays. Western blotting confirms deletion of EEF2K and dephosphorylation of EEF2. Puromycin incorporation provides a direct readout of translation rates, while polysome profiling assesses ribosomal elongation complex formation. MTT and metabolic flux assays gauge changes in cellular energy status, and drug sensitivity screens evaluate therapeutic implications. Flow cytometry enables analysis of viability, apoptosis, and B cell activation markers. This comprehensive toolkit accelerates research on translational control and the therapeutic potential of EEF2K inhibition. For further technical details, please contact Ascent Research.
